Pioglitazone
- Generic Name
- Pioglitazone
- Brand Names
- Actoplus Met, Actos, Duetact, Incresync, Oseni, Tandemact, Pioglitazone Accord, Pioglitazone Actavis
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20N2O3S
- CAS Number
- 111025-46-8
- Unique Ingredient Identifier
- X4OV71U42S
- Background
Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus. It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert in vivo with little consequence. The thiazolidinedione class of medicatio...
- Indication
Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also available in combination with metformin, glimepiride, or alogliptin for the same indication.
- Associated Conditions
- Diabetes, Diabetic Neuropathies, Type 2 Diabetes Mellitus
- Associated Therapies
- -
Pioglitazone Incretin Study
- First Posted Date
- 2008-04-11
- Last Posted Date
- 2011-02-02
- Lead Sponsor
- University of Vermont
- Target Recruit Count
- 24
- Registration Number
- NCT00656864
- Locations
- 🇺🇸
University of Vermont, South Burlington, Vermont, United States
Exercise and Pioglitazone for HIV-Metabolic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2008-03-20
- Last Posted Date
- 2013-10-23
- Target Recruit Count
- 44
- Registration Number
- NCT00639457
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)
- Conditions
- Interventions
- First Posted Date
- 2008-03-17
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 514
- Registration Number
- NCT00637273
- Locations
- 🇲🇽
Research Site, Toluca, Mexico
Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2017-07-19
- Lead Sponsor
- Fernando Holguin
- Target Recruit Count
- 23
- Registration Number
- NCT00634036
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸University of Vermont, Colchester, Vermont, United States
Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease
- Conditions
- Interventions
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- Xin Gao
- Target Recruit Count
- 184
- Registration Number
- NCT00633282
- Locations
- 🇨🇳
Department of Endocrinology and Metabolism,Shanghai Clinical Center of Diabetes,Shanghai Institute of Diabetes,The sixth people's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, Shanghai, China
🇨🇳Endocrinology and Metabolism Department, Zhongshan Hospital, Fudan University,, Shanghai, Shanghai, China
🇨🇳Department of Endocrinology and Metabolism,The Fifth People's Hospital，Fudan University, Shanghai, Shanghai, China
Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2008-02-07
- Last Posted Date
- 2008-02-07
- Lead Sponsor
- Skane University Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT00609856
- Locations
- 🇸🇪
Malmö University Hospital, Malmö, Sweden
Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy
- Conditions
- First Posted Date
- 2008-01-23
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 242
- Registration Number
- NCT00598793
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Renton, Washington, United States
Effect of Pioglitazone on Insulin Resistance and Atherosclerosis in Renal Allograft Recipients Without Diabetes
- Conditions
- Interventions
- First Posted Date
- 2008-01-18
- Last Posted Date
- 2008-01-18
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 83
- Registration Number
- NCT00598013
- Locations
- 🇰🇷
Yonsei University College of Medicine, Seoul, Korea, Republic of
Does Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function
- Conditions
- Interventions
- First Posted Date
- 2008-01-04
- Last Posted Date
- 2013-03-15
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 36
- Registration Number
- NCT00586261
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Mechanisms Underlying Metabolic Syndrome in Obesity
- Conditions
- Interventions
- First Posted Date
- 2007-12-24
- Last Posted Date
- 2017-06-15
- Lead Sponsor
- Philip Kern
- Target Recruit Count
- 70
- Registration Number
- NCT00579813
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸University of Kentucky, Lexington, Kentucky, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.